Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Int J Obes (Lond). 2010 Feb;34(2):374-84. doi: 10.1038/ijo.2009.219. Epub 2009 Oct 20.
The antiobesity effects of suppressed endocannabinoid signaling may rely, at least in part, on changes in lipid fluxes. As fatty acids exert specific effects depending on their level of saturation, we hypothesized that the dietary fatty acid composition would influence the outcome of treatment with a CB(1)-receptor antagonist (rimonabant).
Mice were treated with rimonabant (10 mg kg(-1) body weight per day) or vehicle while equicalorically fed either a low-fat diet (LF), a high-fat (HF) diet or an HF diet in which 10% of the saturated fatty acids (SFAs) were replaced by poly-unsaturated fatty acids (PUFA) from fish oil (FO). Food intake and body weight were registered daily. Indirect calorimetry was performed and feces were collected. After 3 weeks, mice were killed for blood and tissue collection.
Relative to the LF diet, the HF diet caused anticipated metabolic derangements, which were partly reversed by the HF/FO diet. The HF/FO diet, however, was most obesity-promoting despite inhibiting lipogenesis as indicated by low gene expression levels of lipogenic enzymes. On all three diets, rimonabant treatment improved metabolic derangements and led to significantly lower body weight gain than their respective controls. This latter effect appeared largest in the HF/FO group, but occurred without major changes in nutrient absorption and energy expenditure.
The effects of chronic rimonabant treatment on body weight gain occurred irrespective of diet-induced changes in lipogenic activity, food intake and daily energy expenditure, and were, in fact, most pronounced in HF/FO mice. The effects of dietary PUFA replacement in an HF diet on expansion of adipose tissue might allow the favorable effects of dietary PUFA on dyslipidemia and hepatic steatosis. In light of other disadvantageous effects of weight gain, this might be a risky trade-off.
抑制内源性大麻素信号的抗肥胖作用可能至少部分依赖于脂质通量的变化。由于脂肪酸的效力取决于其饱和度水平,我们假设饮食中脂肪酸的组成会影响 CB1 受体拮抗剂(利莫那班)治疗的结果。
用利莫那班(每天 10mg/kg 体重)或载体处理小鼠,同时等热量喂养低脂(LF)饮食、高脂(HF)饮食或 HF 饮食,其中 10%的饱和脂肪酸(SFA)被鱼油(FO)中的多不饱和脂肪酸(PUFA)取代。每天记录食物摄入量和体重。进行间接测热法和收集粪便。3 周后,处死小鼠收集血液和组织。
与 LF 饮食相比,HF 饮食导致预期的代谢紊乱,HF/FO 饮食部分逆转了这些紊乱。然而,HF/FO 饮食尽管抑制了脂肪生成,表明脂肪生成酶的基因表达水平较低,但最能促进肥胖。在所有三种饮食中,利莫那班治疗改善了代谢紊乱,并导致体重增加明显低于各自的对照。后者的效果在 HF/FO 组中最大,但没有主要改变营养吸收和能量消耗。
慢性利莫那班治疗对体重增加的影响与饮食诱导的脂肪生成活性、食物摄入和每日能量消耗的变化无关,实际上在 HF/FO 小鼠中最为明显。HF 饮食中 PUFA 替代对脂肪组织扩张的影响可能允许饮食中 PUFA 对血脂异常和肝脂肪变性的有利影响。鉴于体重增加的其他不利影响,这可能是一个有风险的权衡。